{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:18:54Z","timestamp":1783610334725,"version":"3.55.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Although P2Y purinergic receptor 12 (P2Y12) inhibitors are commonly used in patients with atherosclerotic cardiovascular disease, there are limited data on intracerebral hemorrhage (ICH) associated with use of P2Y12 inhibitors.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare stroke severity, in-hospital mortality, and functional outcomes in ICH among patients receiving P2Y12 inhibitor monotherapy, dual antiplatelet therapy (DAPT) with P2Y12 inhibitor plus aspirin, aspirin monotherapy, or no antiplatelet therapy prior to ICH.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study obtained data from the nationwide Get With The Guidelines\u2013Stroke registry, which contains data from participating hospitals. Participants were patients hospitalized with spontaneous ICH between January 2013 to December 2021. The analysis was completed in January 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Antiplatelet therapy before ICH, defined as any use within 7 days prior to hospital arrival.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were severe stroke at presentation and in-hospital mortality. Severity was assessed using the National Institutes of Health Stroke Scale (NIHSS; range: 0-42, with higher scores indicating greater severity), with a score of 21 or higher indicating severe stroke. Secondary outcomes included in-hospital mortality or discharge to hospice, discharge to home, independent ambulation, and modified Rankin Scale (mRS) score at discharge. An mRS score of 0 to 2 at discharge indicated functional independence.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 252\u202f691 patients included (median [IQR] age, 67 [56-78] years; 134 684 males [53.3%]), 6355 (2.5%) were receiving P2Y12 inhibitor monotherapy, 10\u202f607 (4.2%) were receiving DAPT, 63\u202f299 (25.0%) were receiving aspirin monotherapy, and 172\u202f430 (68.2%) were receiving no antiplatelet agents prior to ICH. Patients taking P2Y12 inhibitors were older and had higher prevalence of cardiovascular risk factors. Overall, 1701 patients (26.8%) receiving P2Y12 monotherapy and 2688 patients (25.3%) receiving DAPT experienced severe ICH (NIHSS score \u226521) compared with 12\u202f952 patients (20.5%) who used aspirin monotherapy and 39 970 (23.2%) patients who received no antiplatelet (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). In-hospital mortality rates were highest in patients using DAPT (24.0%), followed by patients receiving P2Y12 inhibitor monotherapy (23.8%), no antiplatelet (16.8%), and aspirin monotherapy (16.5%) (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). After risk adjustment, patients with prior use of P2Y12 inhibitors were more likely to present with severe stroke (P2Y12 inhibitor monotherapy: adjusted odds ratio [AOR], 1.43 [95% CI, 1.34-1.52];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001; DAPT: AOR, 1.40 [95% CI, 1.33-1.47];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and more likely to die in the hospital (P2Y12 inhibitor monotherapy: AOR, 1.55 [95% CI, 1.46-1.66];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001; DAPT: AOR, 1.61 [95% CI, 1.53-1.71];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) compared with those using aspirin monotherapy. Furthermore, these patients were less likely to be discharged to home, be able to ambulate independently, or have functional independence at discharge. In contrast, there were no statistically significant differences in in-hospital outcomes between aspirin monotherapy and no antiplatelet therapy groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this registry-based cohort study of patients with ICH not associated with anticoagulation, P2Y12 inhibitors, either as monotherapy or in combination with aspirin, were associated with more severe stroke, in-hospital death, worse clinical outcomes, and reduced functional recovery compared with aspirin monotherapy or no antiplatelet therapy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.22239","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:00:31Z","timestamp":1783609231000},"page":"e2622239","source":"Crossref","is-referenced-by-count":0,"title":["P2Y12 Inhibitors and Mortality in Patients Hospitalized With Intracerebral Hemorrhage"],"prefix":"10.1001","volume":"9","author":[{"given":"Chen","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Mac Grory","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine, Durham, North Carolina"},{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Lena","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Alhanti","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ahmanson-UCLA (University of California, Los Angeles) Cardiomyopathy Center, UCLA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee H.","family":"Schwamm","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin N.","family":"Sheth","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric E.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Mess\u00e9","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Saver","sequence":"additional","affiliation":[{"name":"Department of Neurology, UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xian","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Texas Southwestern Medical Center, Dallas"},{"name":"Peter O\u2019Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"3","key":"zoi260622r1","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0000000000001038","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"zoi260622r2","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines.","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"zoi260622r3","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: a guideline from the American Heart Association\/American Stroke Association.","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"12","key":"zoi260622r4","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"issue":"24","key":"zoi260622r5","doi-asserted-by":"publisher","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"issue":"16","key":"zoi260622r6","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi260622r7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"issue":"12","key":"zoi260622r8","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1161\/CIRCRESAHA.114.302737","article-title":"Antiplatelet and anticoagulation therapy for acute coronary syndromes.","volume":"114","author":"Bhatt","year":"2014","journal-title":"Circ Res"},{"issue":"2","key":"zoi260622r9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events.","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"10508","key":"zoi260622r10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","article-title":"Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis.","volume":"406","author":"Valgimigli","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"zoi260622r11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1067\/mhj.2000.108239","article-title":"Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.","volume":"140","author":"Bhatt","year":"2000","journal-title":"Am Heart J"},{"issue":"3","key":"zoi260622r12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260622r13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260622r14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/jtim-2023-0138","article-title":"Dual antiplatelet instead of intravenous thrombolysis for minor nondisabling acute ischemic stroke: a perspective from China.","volume":"12","author":"Cui","year":"2024","journal-title":"J Transl Int Med"},{"issue":"13","key":"zoi260622r15","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.jacc.2021.07.048","article-title":"Intracranial hemorrhage during dual antiplatelet therapy: JACC review topic of the week.","volume":"78","author":"Ha","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"zoi260622r16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209442","article-title":"Association of antithrombotic drug use with incident intracerebral hemorrhage location.","volume":"102","author":"Boe","year":"2024","journal-title":"Neurology"},{"key":"zoi260622r17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2147\/CLEP.S493499","article-title":"Association of prior antithrombotic drug use with 90-day mortality after intracerebral hemorrhage.","volume":"16","author":"J\u00f8rgensen","year":"2024","journal-title":"Clin Epidemiol"},{"issue":"15","key":"zoi260622r18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1212\/WNL.0b013e3181f735e5","article-title":"Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review.","volume":"75","author":"Thompson","year":"2010","journal-title":"Neurology"},{"issue":"7","key":"zoi260622r19","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/STROKEAHA.117.016290","article-title":"Association between previous use of antiplatelet therapy and intracerebral hemorrhage outcomes.","volume":"48","author":"Khan","year":"2017","journal-title":"Stroke"},{"issue":"5","key":"zoi260622r20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1001\/jama.2017.21917","article-title":"Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality.","volume":"319","author":"Inohara","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"zoi260622r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37438","article-title":"Clinical characteristics and outcomes associated with oral anticoagulant use among patients hospitalized with intracerebral hemorrhage.","volume":"4","author":"Xian","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi260622r22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12028-011-9619-3","article-title":"Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage.","volume":"16","author":"Naidech","year":"2012","journal-title":"Neurocrit Care"},{"issue":"2","key":"zoi260622r23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1056\/NEJMc1409373","article-title":"Inefficacy of platelet transfusion to reverse ticagrelor.","volume":"372","author":"Godier","year":"2015","journal-title":"N Engl J Med"},{"issue":"10038","key":"zoi260622r24","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial.","volume":"387","author":"Baharoglu","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"zoi260622r25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/CIRCOUTCOMES.109.921858","article-title":"Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in Get With The Guidelines\u2013Stroke.","volume":"3","author":"Fonarow","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"zoi260622r26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ahj.2011.12.012","article-title":"Data quality in the American Heart Association Get With The Guidelines\u2013Stroke (GWTG-Stroke): results from a national data validation audit.","volume":"163","author":"Xian","year":"2012","journal-title":"Am Heart J"},{"issue":"4","key":"zoi260622r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106348","article-title":"National Institutes of Health Stroke Scale correlates well with initial intracerebral hemorrhage volume.","volume":"31","author":"Farooq","year":"2022","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"zoi260622r28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/xJAHA.111.000034","article-title":"Relationship of National Institutes of Health Stroke Scale to 30-day mortality in Medicare beneficiaries with acute ischemic stroke.","volume":"1","author":"Fonarow","year":"2012","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"zoi260622r29","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1161\/01.STR.31.6.1429","article-title":"Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice.","volume":"31","author":"Duncan","year":"2000","journal-title":"Stroke"},{"issue":"11","key":"zoi260622r30","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1161\/STROKEAHA.114.005620","article-title":"Racial\/ethnic differences in process of care and outcomes among patients hospitalized with intracerebral hemorrhage.","volume":"45","author":"Xian","year":"2014","journal-title":"Stroke"},{"issue":"4","key":"zoi260622r31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/EDE.0b013e3181a819a1","article-title":"Overadjustment bias and unnecessary adjustment in epidemiologic studies.","volume":"20","author":"Schisterman","year":"2009","journal-title":"Epidemiology"},{"issue":"1","key":"zoi260622r32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.117.005795","article-title":"Impact of clopidogrel therapy on mortality and cancer in patients with cardiovascular and cerebrovascular disease: a patient-level meta-analysis.","volume":"11","author":"Elmariah","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"issue":"19","key":"zoi260622r33","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction.","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi260622r34","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes.","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"issue":"10204","key":"zoi260622r35","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","article-title":"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.","volume":"394","author":"Bhatt","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"zoi260622r36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA.","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi260622r37","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00415-025-13339-y","article-title":"Characteristics of intracerebral hemorrhage associated with dual antiplatelet treatment.","volume":"272","author":"Morotti","year":"2025","journal-title":"J Neurol"},{"issue":"5","key":"zoi260622r38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2019.02.080","article-title":"Antithrombotics: from aspirin to DOACs in coronary artery disease and atrial fibrillation.","volume":"74","author":"Verheugt","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"zoi260622r39","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa2508808","article-title":"Early discontinuation of aspirin after PCI in low-risk acute myocardial infarction.","volume":"393","author":"Tarantini","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi260622r40","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: a guideline from the American Heart Association\/American Stroke Association.","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"issue":"12","key":"zoi260622r41","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1111\/jth.13511","article-title":"Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects.","volume":"14","author":"Teng","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"19","key":"zoi260622r42","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1056\/NEJMoa1901778","article-title":"Antibody-based ticagrelor reversal agent in healthy volunteers.","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi260622r44","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/STROKEAHA.120.032550","article-title":"Intracerebral hemorrhage incidence, mortality, and association with oral anticoagulation use: a population study.","volume":"52","author":"Fernando","year":"2021","journal-title":"Stroke"},{"issue":"9","key":"zoi260622r45","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaneurol.2022.1991","article-title":"One-year outcome trajectories and factors associated with functional recovery among survivors of intracerebral and intraventricular hemorrhage with initial severe disability.","volume":"79","author":"Shah","year":"2022","journal-title":"JAMA Neurol"},{"issue":"6","key":"zoi260622r46","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1161\/STROKEAHA.124.046527","article-title":"Twenty years of Get With The Guidelines-Stroke: celebrating past successes, lessons learned, and future challenges.","volume":"55","author":"Reeves","year":"2024","journal-title":"Stroke"},{"issue":"11","key":"zoi260622r47","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1161\/STROKEAHA.124.048174","article-title":"Twenty years of sustained improvement in quality of care and outcomes for patients hospitalized with stroke or transient ischemic attack: data from The Get With The Guidelines-Stroke program.","volume":"55","author":"Xian","year":"2024","journal-title":"Stroke"},{"key":"zoi260622r43","author":"Bhatt","year":"2022"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851453\/jin_2026_oi_260622_1782932621.19846.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:00:31Z","timestamp":1783609231000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.22239","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}